Cargando…
Is Platinum Present in Blood and Urine from Treatment Givers during Hyperthermic Intraperitoneal Chemotherapy?
Background. In selected patients with peritoneal carcinomatosis (PC) originating from colorectal cancer (CRC) the high dosage of oxaliplatin (460 mg/m(2)) is recommended for hyperthermic intraperitoneal chemotherapy (HIPEC), which may be a health risk to those administering the drug. The aim of this...
Autores principales: | Näslund Andréasson, Sara, Anundi, Helena, Thorén, Sig-Britt, Ehrsson, Hans, Mahteme, Haile |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902751/ https://www.ncbi.nlm.nih.gov/pubmed/20631909 http://dx.doi.org/10.1155/2010/649719 |
Ejemplares similares
-
Polycyclic Aromatic Hydrocarbons in Electrocautery Smoke during Peritonectomy Procedures
por: Näslund Andréasson, Sara, et al.
Publicado: (2012) -
Coagulopathy and Venous Thromboembolic Events Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Dranichnikov, Paul, et al.
Publicado: (2021) -
Pulmonary influences on early post-operative recovery in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: a retrospective study
por: Arakelian, Erebouni, et al.
Publicado: (2012) -
Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei
por: Bjersand, Kathrine, et al.
Publicado: (2015) -
Anesthetic implications in hyperthermic intraperitoneal chemotherapy
por: Gupta, Nishkarsh, et al.
Publicado: (2019)